JP2013510102A - リン酸エステルの合成 - Google Patents
リン酸エステルの合成 Download PDFInfo
- Publication number
- JP2013510102A JP2013510102A JP2012537311A JP2012537311A JP2013510102A JP 2013510102 A JP2013510102 A JP 2013510102A JP 2012537311 A JP2012537311 A JP 2012537311A JP 2012537311 A JP2012537311 A JP 2012537311A JP 2013510102 A JP2013510102 A JP 2013510102A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- carbon atoms
- formula
- alkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003014 phosphoric acid esters Chemical class 0.000 title abstract description 4
- 230000015572 biosynthetic process Effects 0.000 title description 18
- 238000003786 synthesis reaction Methods 0.000 title description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims description 31
- 125000004432 carbon atom Chemical group C* 0.000 claims description 28
- -1 tetraols Chemical class 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 150000002390 heteroarenes Chemical class 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000000524 functional group Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 230000000865 phosphorylative effect Effects 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 239000000010 aprotic solvent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 150000002009 diols Chemical class 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- 150000003973 alkyl amines Chemical group 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 150000001491 aromatic compounds Chemical class 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 150000004072 triols Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 14
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- PYTMBSDYMPHFOQ-UHFFFAOYSA-N 2,2,2-trichloro-n-[4-(trifluoromethyl)phenyl]acetamide Chemical compound FC(F)(F)C1=CC=C(NC(=O)C(Cl)(Cl)Cl)C=C1 PYTMBSDYMPHFOQ-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- MWEZHNCHKXEIBJ-RWFZIKKDSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound C1C=C2C[C@@H](OP([O-])(=O)OCC[N+](C)(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 MWEZHNCHKXEIBJ-RWFZIKKDSA-N 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- VTDOEFXTVHCAAM-UHFFFAOYSA-N 4-methylpent-3-ene-1,2,3-triol Chemical compound CC(C)=C(O)C(O)CO VTDOEFXTVHCAAM-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 150000003852 triazoles Chemical class 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- YHHSONZFOIEMCP-UHFFFAOYSA-M choline phosphate(1-) Chemical compound C[N+](C)(C)CCOP([O-])([O-])=O YHHSONZFOIEMCP-UHFFFAOYSA-M 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000005580 one pot reaction Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 2
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000006038 hexenyl group Chemical group 0.000 description 2
- 125000005980 hexynyl group Chemical group 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- CTKINSOISVBQLD-GSVOUGTGSA-N (R)-Glycidol Chemical compound OC[C@@H]1CO1 CTKINSOISVBQLD-GSVOUGTGSA-N 0.000 description 1
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- FLGMAMYMYDIKLE-UHFFFAOYSA-N chloro hypochlorite;phosphane Chemical compound P.ClOCl FLGMAMYMYDIKLE-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940112042 peripherally acting choline derivative muscle relaxants Drugs 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004346 phenylpentyl group Chemical group C1(=CC=CC=C1)CCCCC* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000001394 phosphorus-31 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000001189 phytyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])([H])[C@@](C([H])([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])[C@@](C([H])([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
- C07F9/6518—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
a)式IIで示されるヘテロ芳香族化合物
−CH−CH−CH−、
−Z−CH−CH−、
−CH−Z−CH−、
−CH−CH−Z−、
−CH−Z−、
−Z−CH−または
−Z−Z−
を表し、
ここで、Zは、各々の場合互いに独立して、芳香族系を与えるようにO、S、NおよびNHからなる群より選択される;
b)−OR4、
式中、R4は、1〜20個の炭素原子を有する直鎖または分岐アルキル、2〜20個の炭素原子および一または二以上の二重結合を有する直鎖または分岐アルケニル、2〜20個の炭素原子および一または二以上の三重結合を有する直鎖または分岐アルキニル、または、炭素原子数1〜6のアルキル基により置換されていてよい3〜24個の炭素原子を有する飽和、部分的もしくは完全不飽和シクロアルキルを表し、
ここで、R4は、−OR1、−NR1 2、−CN、−C(O)NR1 2、−COOR1、−C(=O)R1、−SO2NR1 2または芳香族基のような置換基により置換されていてよく、これらは、任意に、従来の保護基が設けられ、一または二以上の炭素原子がヘテロ原子により置換されていてよく、R1は、H、C1−C6−アルキル、C3−C7−シクロアルキル、非置換または置換フェニルを表す;
c)−O−)
で示される化合物を調製する方法であって、第1のステップにおいて、オキシ塩化リンをN−含有ヘテロ芳香族化合物と反応させ、次のステップにおいて、ヘテロ芳香族化合物を、任意に、OH官能基を有する化合物により少なくとも部分的に置換することを特徴とする方法に関する。
ここで、R5およびR6は、−OR1、−NR1 2、−CN、−C(O)NR1 2、−COOR1、−C(=O)R1、−SO2NR1 2または芳香族基のような置換基により置換されていてよく、これらは、任意に、従来の保護基が設けられ、一または二以上の炭素原子がヘテロ原子により置換されていてよく、R1は、H、C1−C6−アルキル、C3−C7−シクロアルキル、非置換または置換フェニルを表し、
基X、YおよびR4は、先に定義した意味を有する)。
記載した方法の第1のステップにおける反応は、室温でまたは冷却して行われる。反応は、好ましくは、0℃を超える温度で行われる。反応は、特に好ましくは、10〜0℃の間で行われる。
バッチ:
イソプロピリデングリセロール 25.83g
オキシ塩化リン 29.94g
トリエチルアミン 59.31g + 10g
トリアゾール 40.5g + 2g
THF(乾燥) 500ml
トシル酸コリン 53.79g
H2O 50ml
70%メタノール/水 300ml
0.1 N HCl 50ml
高純度アンバーライト混合床イオン交換体(Roth製) 900g
エタノール(無水) 400ml
(NH4)2MoO4 1g
Ce(IV)SO4 20mg
10% H2SO4。
Bruker Advance 500(DRX)スペクトロメーター(1H共鳴振動数500MHz);溶媒は特記しない限りCDCl3;対照物質1H−NMR:内部標準としてのテトラメチルシラン、31P−NMR:外部標準としてのD2O中のリン酸
DMSO中の産物グリセロホスホコリン(X)の1H−NMR:5.60ppm s,4.93ppm s,4.05ppm s,3.65−3.71ppm m,3.47−3.53ppm m,3.13ppm s。
産物の1H−NMR(500MHz,CDCl3):δ(ppm)=4.29(s,br,2H),3.90(m,2H),3.68(m,2H),3.24(s,9H),2.35(s,1H),2.22(m,2H),1.65(m,2H),1.53(m,2H),1.45−1.3(m,10H)。
産物の1H−NMR(500MHz,CDCl3):δ(ppm)=4.49(s,br,1H),4.28(m,3H),4.15(m,1H),3.67(m,2H),3.36(s,9H),3.36(s,3H),3.23(s,9H),1.46(s,9H)。
産物の1H−NMR(500MHz,CDCl3):δ(ppm)=5.75(s,2H),4.91(s,1H),4.21(m,2H),3.89(m,2H),3.21(s,9H),2.65(m,2H),2.45(m,2H)。
産物の1H−NMR(500MHz,CDCl3):δ(ppm)=5.35(m,1H),4.40(m,2H),4.31(m,2H),3.81(m,2H),3.59(m,2H),3.31(s,9H),1.6(s,3H),1.6−0.9(m,18H),0.82(m,12H)。
Claims (13)
- 式I:
a)式IIで示されるヘテロ芳香族化合物
−CH−CH−CH−、
−Z−CH−CH−、
−CH−Z−CH−、
−CH−CH−Z−、
−CH−Z−、
−Z−CH−または
−Z−Z−
を表し、
ここで、Zは、各々の場合互いに独立して、芳香族系を与えるようにO、S、NおよびNHからなる群より選択される;
b)−OR4、
式中、R4は、1〜20個の炭素原子を有する直鎖または分岐アルキル、2〜20個の炭素原子および一または二以上の二重結合を有する直鎖または分岐アルケニル、2〜20個の炭素原子および一または二以上の三重結合を有する直鎖または分岐アルキニル、または、炭素原子数1〜6のアルキル基により置換されていてよい3〜24個の炭素原子を有する飽和、部分的もしくは完全不飽和シクロアルキルを表し、
ここで、R4は、−OR1、−NR1 2、−CN、−C(O)NR1 2、−COOR1、−C(=O)R1、−SO2NR1 2または芳香族基のような置換基により置換されていてよく、これらは、任意に、従来の保護基が設けられ、一または二以上の炭素原子がヘテロ原子により置換されていてよく、R1は、H、C1−C6−アルキル、C3−C7−シクロアルキル、非置換または置換フェニルを表す;
c)−O−)
で示される化合物を調製する方法であって、第1のステップにおいて、オキシ塩化リンをN−含有ヘテロ芳香族化合物と反応させ、次のステップにおいて、ヘテロ芳香族化合物を、任意に、OH官能基を有する化合物により少なくとも部分的に置換することを特徴とする方法。 - 式Iで示される化合物が、式Ia、Ib、Ic、IdおよびIeから選択されることを特徴とする、請求項1に記載の方法:
ここで、R5およびR6は、−OR1、−NR1 2、−CN、−C(O)NR1 2、−COOR1、−C(=O)R1、−SO2NR1 2または芳香族基のような置換基により置換されていてよく、これらは、任意に、従来の保護基が設けられ、一または二以上の炭素原子がヘテロ原子により置換されていてよく、R1は、H、C1−C6−アルキル、C3−C7−シクロアルキル、非置換または置換フェニルを表し、
基X、YおよびR4は、請求項1による意味を有する)。 - 第1のステップの反応を非プロトン性溶媒、好ましくはアセトニトリル、酢酸エチル、ジオキサン、テトラヒドロフラン、テトラメチルシラン、ジメチルホルムアミド、ジメチルスルホキシド、アセトン、ジエチルエーテル、メチルtert−ブチルエーテル、シクロヘキサン、ジメチルアセトアミド、スルホラン、N−メチルピロリドンおよびジクロロメタンからなる群より選択される非プロトン性溶媒中で行うことを特徴とする、請求項1または2に記載の方法。
- 第1のステップの反応をN−含有塩基、好ましくは第3アルキルアミンから選択されるN−含有塩基の存在下に行うことを特徴とする、請求項1から3のいずれかに記載の方法。
- 第1のステップの反応を室温で、または冷却、好ましくは0℃よりは高い温度に冷却して行うことを特徴とする、請求項1から4のいずれかに記載の方法。
- OH官能基を有する化合物が、生体分子または生体分子誘導体、好ましくはモノアルコール、ジオール、トリオール、テトラオール、糖、ポリオール、OH−含有アミノ酸またはOH−含有核酸から選択されるものであることを特徴とする、請求項1から5のいずれかに記載の方法。
- OH−含有化合物との反応が、室温または低温、好ましくは0℃未満、特に好ましくは−25℃未満の温度で行われることを特徴とする、請求項1から6のいずれかに記載の方法。
- 式Iで示される化合物がsyn−グリセロ−3−ホスホコリンであることを特徴とする、請求項1から9のいずれかに記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102009052034A DE102009052034A1 (de) | 2009-11-05 | 2009-11-05 | Synthese von Phosphorestern |
DE102009052034.1 | 2009-11-05 | ||
PCT/EP2010/006158 WO2011054429A1 (de) | 2009-11-05 | 2010-10-08 | Synthese von phosphorestern |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013510102A true JP2013510102A (ja) | 2013-03-21 |
JP5782043B2 JP5782043B2 (ja) | 2015-09-24 |
Family
ID=43332858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012537311A Expired - Fee Related JP5782043B2 (ja) | 2009-11-05 | 2010-10-08 | リン酸エステルの合成 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8940907B2 (ja) |
EP (1) | EP2496586B1 (ja) |
JP (1) | JP5782043B2 (ja) |
CA (1) | CA2779755A1 (ja) |
DE (1) | DE102009052034A1 (ja) |
DK (1) | DK2496586T3 (ja) |
ES (1) | ES2449692T3 (ja) |
IL (1) | IL219467A0 (ja) |
PL (1) | PL2496586T3 (ja) |
TW (1) | TWI499594B (ja) |
WO (1) | WO2011054429A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102584926B (zh) * | 2012-01-12 | 2014-10-15 | 浙江大学 | 利用基于胆固醇和磷酸胆碱两亲小分子制备超分子水凝胶的方法 |
CN103304594B (zh) * | 2013-06-18 | 2015-07-08 | 上海科利生物医药有限公司 | 一种L-α-甘油磷酸胆碱的制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60248676A (ja) * | 1984-05-25 | 1985-12-09 | Taiyo Yakuhin Kogyo Kk | N−置換イミダゾ−ル類の製造法 |
JPS6156191A (ja) * | 1984-08-27 | 1986-03-20 | Toagosei Chem Ind Co Ltd | リン酸トリエステル化合物の製造法 |
EP0486100A1 (en) * | 1990-11-15 | 1992-05-20 | MAGIS FARMACEUTICI S.p.A. | Process for preparing alpha-glycerophosphorylcholine |
WO1998055487A1 (en) * | 1997-06-04 | 1998-12-10 | Biocompatibles Limited | Phosphate compounds |
US6140496A (en) * | 1990-10-09 | 2000-10-31 | Benner; Steven Albert | Precursors for deoxyribonucleotides containing non-standard nucleosides |
WO2007145476A1 (en) * | 2006-06-14 | 2007-12-21 | Kim, Hyun Joo | A process for preparation of l-alpha-glycerophosphoryl choline |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU86347A1 (fr) | 1986-03-06 | 1987-11-11 | Oreal | Compositions pour la coloration de la peau a base de derives d'indole |
JP3839857B2 (ja) | 1994-09-20 | 2006-11-01 | 塩野義製薬株式会社 | エーテル型チオリン脂質化合物の製造方法 |
-
2009
- 2009-11-05 DE DE102009052034A patent/DE102009052034A1/de not_active Withdrawn
-
2010
- 2010-10-08 US US13/508,114 patent/US8940907B2/en not_active Expired - Fee Related
- 2010-10-08 JP JP2012537311A patent/JP5782043B2/ja not_active Expired - Fee Related
- 2010-10-08 CA CA2779755A patent/CA2779755A1/en not_active Abandoned
- 2010-10-08 PL PL10763324T patent/PL2496586T3/pl unknown
- 2010-10-08 EP EP10763324.0A patent/EP2496586B1/de not_active Not-in-force
- 2010-10-08 ES ES10763324.0T patent/ES2449692T3/es active Active
- 2010-10-08 DK DK10763324.0T patent/DK2496586T3/en active
- 2010-10-08 WO PCT/EP2010/006158 patent/WO2011054429A1/de active Application Filing
- 2010-11-04 TW TW099137980A patent/TWI499594B/zh active
-
2012
- 2012-04-29 IL IL219467A patent/IL219467A0/en not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60248676A (ja) * | 1984-05-25 | 1985-12-09 | Taiyo Yakuhin Kogyo Kk | N−置換イミダゾ−ル類の製造法 |
JPS6156191A (ja) * | 1984-08-27 | 1986-03-20 | Toagosei Chem Ind Co Ltd | リン酸トリエステル化合物の製造法 |
US6140496A (en) * | 1990-10-09 | 2000-10-31 | Benner; Steven Albert | Precursors for deoxyribonucleotides containing non-standard nucleosides |
EP0486100A1 (en) * | 1990-11-15 | 1992-05-20 | MAGIS FARMACEUTICI S.p.A. | Process for preparing alpha-glycerophosphorylcholine |
WO1998055487A1 (en) * | 1997-06-04 | 1998-12-10 | Biocompatibles Limited | Phosphate compounds |
WO2007145476A1 (en) * | 2006-06-14 | 2007-12-21 | Kim, Hyun Joo | A process for preparation of l-alpha-glycerophosphoryl choline |
Non-Patent Citations (2)
Title |
---|
JPN6014046615; Molecular Pharmaceutics 2(6), 2005, 449-461 * |
JPN6014046616; Chemische Berichte 101(4), 1968, 1141-7 * |
Also Published As
Publication number | Publication date |
---|---|
US20120215006A1 (en) | 2012-08-23 |
TWI499594B (zh) | 2015-09-11 |
CA2779755A1 (en) | 2011-05-12 |
PL2496586T3 (pl) | 2014-05-30 |
IL219467A0 (en) | 2012-06-28 |
JP5782043B2 (ja) | 2015-09-24 |
TW201139456A (en) | 2011-11-16 |
EP2496586B1 (de) | 2013-12-18 |
ES2449692T3 (es) | 2014-03-20 |
DE102009052034A1 (de) | 2011-05-12 |
WO2011054429A1 (de) | 2011-05-12 |
EP2496586A1 (de) | 2012-09-12 |
DK2496586T3 (en) | 2014-03-24 |
US8940907B2 (en) | 2015-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU762757B2 (en) | Antiviral purine derivatives | |
ES2748505T3 (es) | Métodos para la preparación de oxazolidinonas y composiciones que las contienen | |
CA1117965A (en) | Structural analogs of natural phospholipids | |
EP3106465B1 (en) | Method for preparing racemic or optically active glycerophosphoryl choline | |
JP5782043B2 (ja) | リン酸エステルの合成 | |
CZ305396A3 (en) | Process for preparing purines and intermediates for such preparation | |
US4163748A (en) | Propane-1,3-diol phosphatides and method of preparing the same | |
AU657554B2 (en) | Dialkyl (dialkoxyphosphinyl)methyl phosphates as anti-inflammatory agents | |
JPH041759B2 (ja) | ||
CA2511753C (en) | Phospholipid derivatives | |
CN109824725A (zh) | 一种4-磷酸酯-2h-色烯衍生物的制备方法 | |
Kong et al. | A facile synthesis of ω-aminoalkyl ammonium hydrogen phosphates | |
Xu et al. | Synthesis of new potential chelating agents: Catechol–bisphosphonate conjugates for metal intoxication therapy | |
JPS5888396A (ja) | アミノメチルホスホン酸の製造方法 | |
US6566545B2 (en) | Menthol derivatives and process for preparing the same | |
Cheng‐Xiang et al. | Synthesis of 1, 2‐and 1, 3‐cyclic phospholipid conjugates of N1‐(2‐furanidyl)‐N3‐(2‐hydroxyethyl)‐5‐fluorouracil | |
JP7374533B2 (ja) | 新規オキサゾリジノン系化合物及びその製造方法 | |
AU2006219790B2 (en) | Novel derivatives of phosphinic amino acids, preparation method thereof and pharmaceutical compositions containing same | |
RU2394829C1 (ru) | Способ получения n-триметилсилиламидохлорангидрида метилфосфоновой кислоты | |
Bykhovskaya et al. | Synthesis of 1, 2-azaphospholanes containing an amino acid fragment | |
JP2004256456A (ja) | 2−ブロモエチルジアルキルホスファイト、その製造方法、およびそれを用いたリン酸エステル誘導体の製造方法 | |
JPH0437839B2 (ja) | ||
CN112142795A (zh) | 一种硒唑二膦酸化合物及其制备方法 | |
Pevzner | Synthesis of 4-functionalyzed 2, 3-bis (diethoxyphosphorylmethyl) furans | |
RU2110521C1 (ru) | Способ получения гексагидрата тринатриевой соли фосфонмуравьиной кислоты |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131004 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20140414 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20141016 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150203 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150310 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150525 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150707 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150716 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5782043 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |